针对PI3K的异形选择性向:是时候考虑新的机会了吗?
Davide Cirillo1, Marta Diceglie1, Marc Nazaré1
1Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Campus Berlin-Buch, Berlin, Germany.
Trends in pharmacological sciences
|July 12, 2023
概括
酸-3-酶 (PI3Ks) 是癌症等疾病的关键药物标. 新的研究探索PI3KII类抑制剂,以克服当前治疗的挑战并改善患者的治疗结果.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 酸-3-酶 (PI3Ks) 是关键的信号酶,与许多人类疾病有关,包括癌症,血栓症和肺部疾病.
- 通过成功开发和批准异形选择性I类抑制剂,PI3Ks的治疗相关性得到了强调.
研究的目的:
- 审查最近在开发同型选择性PI3K抑制剂方面的进展.
- 突出针对PI3KII类异型的治疗潜力.
- 强调对PI3K相关病理的多样化药理学工具的需求.
主要方法:
- 关于PI3K抑制剂开发的最近重要发现的文献综述.
- 专注于异型选择性抑制剂,特别是PI3KII类.
- 与PI3K抑制剂治疗相关的临床发现的分析.
主要成果:
- 成功开发异形选择性I类PI3K抑制剂验证了PI3K作为治疗点.
- 已经出现了临床挑战,例如由于持续的目标抑制导致药物耐受性差.
- PI3KII类异型代表了治疗干预的未经探索的领域.
结论:
- 进一步开发PI3K抑制剂是有必要的,以增强临床益处.
- 探索新的向方式和PI3KII类异型至关重要.
- 扩大药理学工具的武器库将改善PI3K介导疾病的治疗选择.
更多相关视频
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
9.2K
10:52Radiolabeling and Quantification of Cellular Levels of Phosphoinositides by High Performance Liquid Chromatography-coupled Flow Scintillation
Published on: January 6, 2016
10.5K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Phosphoinositides and PIPs
8.6K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.6K
The JAK-STAT Signaling Pathway
9.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.0K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
